CLSA



Indiabulls Housing

Rs1,298.55 - BUY



We appreciate your support in the **Asiamoney Brokers Poll**. Please click here to use our voting matrix for this year.

Prakhar Sharma

prakhar.sharma@clsa.com +91 22 6650 5058

Aashish Agarwal

+91 22 6650 5075

3 August 2018

India

Financial services

Reuters INBF.NS Bloomberg IHFL IS

Priced on 2 August 2018 CNX Nifty @ 11,244.7

12M hi/lo Rs1,421.15/1,108.35

12M price target Rs1,700.00 **±% potential** +31%

Shares in issue 426.6m Free float (est.) 78.4%

Market cap US\$8,084m

3M ADV US\$35.1m

Foreign s'holding 54.6%

Major shareholders

Promoters 21.6% Foreign holding 54.6%

Stock performance (%)

| | 1M | 3M | 12M |
|------------|--|----------|-------|
| Absolute | 16.5 | 0.0 | 8.6 |
| Relative | 10.4 | (4.6) | (2.6) |
| Abs (US\$) | 16.7 | (2.2) | 1.8 |
| 1,595 (| Rs) | (%) | - 150 |
| 1,400 - | AND VOICE | | M |
| 1,205 - | \.\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ | Mary Mr. | 100 |
| 1,010 - | W | | - 50 |
| 815 | N 11/10 | | |
| 620 | V | | 0 |
| Aug-16 | Feb-17 Aug-1 | | |
| | Indiabulls HomeonRel to Nifty (| | |

Source: Bloomberg

Steady core; IndAS accretive

Healthy growth to drive compounding-led returns; BUY stays

For 1QFY19, Indiabulls Housing Finance (IHFL) reported IndAS profit of Rs11bn, up 30% YoY. The key positive was the healthy growth in AUMs (up 33% YoY) and QoQ expansion in spreads despite increase in funding costs. While rise in share of housing loans and cautious growth in LAP help to derisk book, higher growth in corp loans with rising share of developer loans (vs LRD) will offset some of that. Transition to IndAS can lift net worth by ~18%, as it includes MTM gains on stake in OakNorth and DTL reversal; even earnings should be higher. IHFL's stress loans per IndAS (stage 3) are in line with gross NPLs at 0.8% of AUM (this is a different from the case with HDFC Ltd) and mgmt has retained ad-hoc provisions of Rs10.5bn (0.8% of AUM). We raise earnings estimates by 3-4% to factor in the changes per IndAS and see 23% Cagr in profit over FY18-21CL and retain BUY with a TP of Rs1,700 (was Rs1,650).

Healthy growth and spreads stable; high growth in construction financing

The key positive in IHFL's result was 33% growth in AUMs, led by a 41% rise in housing loans whose share has risen from 57% one year back to 60% now. While the rise in share of home loans and cautious growth in LAP (18% YoY) are derisking the book, some of this is getting offset by high growth in corporate segment and rising share of construction finance vis-à-vis low risk segments (like LRD); although mgmt believes quality of developers is strong. Encouragingly, the spreads expanded 12bp QoQ to 3.2% (flat YoY) aided by rate hikes and access to lower cost of funds like ECBs/CPs etc.

IndAS transition lifts net worth by 18% and accretive to earnings

IHFL's transition to IndAS is accretive to net worth and earnings: (1) IndAS based net worth is ~18% higher than Indian GAAP aided by MTM gain on investment in OakNorth and reversal of Deferred Tax Liability (DTL), (2) earnings should be a tad higher, as lower tax rate and credit costs will offset lower NII and higher costs (as cost of zero coupon bonds and Esops is amortised). IHFL's stress loans per IndAS (stage 3) at 0.8% of AUM are largely in line with gross NPLs and credit costs will be lower, as it will be based on actual loss experience; it is also carrying Rs10.5bn of ad-hoc provisions (0.8% of loans).

Retain BUY

We raise earnings estimates by 3-4% to factor in the changes per IndAS and see 23% Cagr in profit over FY18-21CL (but not fully like to like). We retain BUY with a 12-month TP of Rs1,700 (earlier Rs1,650) based on 3.2x Jun-20CL adjusted PB.

| Financials | | | | | |
|--------------------------|--------|--------|--------|--------|---------|
| Year to 31 March | 17A | 18A | 19CL | 20CL | 21CL |
| Operating profit (Rsm) | 45,547 | 60,969 | 66,016 | 84,376 | 105,716 |
| Net profit (Rsm) | 29,064 | 38,474 | 45,699 | 57,990 | 72,403 |
| NP forecast change (%) | - | - | 3.0 | 4.2 | 4.4 |
| EPS (Rs) | 69 | 90 | 107 | 136 | 170 |
| CL/consensus (10) (EPS%) | - | - | 102 | 105 | 106 |
| EPS growth (% YoY) | 14 | 32 | 18 | 27 | 25 |
| Core ROA (%) | 2.9 | 3.0 | 3.0 | 3.0 | 3.0 |
| Core ROE (%) | 23 | 28 | 29 | 29 | 31 |
| PE (x) | 19 | 14 | 12 | 10 | 8 |
| Adjusted PB (x)* | 4.5 | 4.0 | 3.0 | 2.6 | 2.2 |
| Dividend yield (%) | 2.1 | 3.2 | 3.1 | 3.7 | 4.4 |

^{*}Adjusted for 100% NPL coverage. Source: Company, CLSA



We would like to thank Evalueserve for its help in preparing our research reports. Bhavik Mehta (Autos, IT); Kamal Verma (Banking & Financial Services); Kushal Shah (Midcaps), Mihir Manohar (Capital Goods, Utilities, Power); and Suraj Yadav (Cement, Oil & Gas) provide research support services to CLSA.

| Su | | |
|----|--|----|
| | | Su |

NII growth lagged AUM growth - spreads were stable, but margins were down

Lower provisions aided strong growth in earnings

AUM growth is led by home loan growth

> Gross stage 3 loans are similar to gross NPLs for **Indiabulls Housing**

Total provisions (including floating) are 1.3% of total AUM

Spreads expanded QoQ but stable YoY

| Summary of 1QFY19 results under IndAS | | | |
|--|---------|-----------|---------|
| (Rsm) | 1QFY18 | 1QFY19 | (% YoY) |
| Net interest income | 13,840 | 16,900 | 22% |
| Other income (includes securitisation gains) | 635 | 462 | (27%) |
| Total income | 14,475 | 17,362 | 20% |
| Costs | 1,871 | 2,689 | 44% |
| Operating profit | 12,604 | 14,673 | 16% |
| Provisions | 1,985 | 648 | (67%) |
| Profit before tax | 10,619 | 14,024 | 32% |
| Tax | 2,571 | 3,538 | 38% |
| Profit after tax | 8,049 | 10,487 | 30% |
| Share of profit (loss) of associate | 46 | 60 | 31% |
| Profit after minority interest | 8,095 | 10,547 | 30% |
| Total comprehensive income | 7,778 | 10,380 | 33% |
| AUM (Rsm) | 944,510 | 1,259,630 | 33% |
| - Mortgages | 739,030 | 998,050 | 35% |
| - Home loans | 535,027 | 757,040 | 41% |
| - LAP | 204,003 | 241,010 | 18% |
| - Corporate | 204,110 | 260,480 | 28% |
| Borrowings (Rsm) | 884,700 | 1,159,900 | 31% |
| - Bank loans | 346,000 | 417,100 | 21% |
| - Bonds, NCDs | 509,600 | 695,500 | 36% |
| - Others | 29,100 | 47,300 | 63% |
| Asset quality | | | |
| Gross NPL/stage 3 loans (Rsm) | 7,570 | 9,800 | 29% |
| Net NPL/stage 3 loans (Rsm) | 5,745 | 7,350 | 28% |
| Gross NPL (% of AUM) | 0.8% | 0.8% | -2bps |
| Net NPL (% of AUM) | 0.6% | 0.6% | -3bps |
| Coverage (% of gross NPL) | 24% | 25% | 89bps |
| Total provisions (% of AUM)^ | Na | 1.3% | |
| | | | |

[^]Includes excess provisions held in excess of what is required under ECL model. Source: Company, CLSA

Figure 2

| Trend in spreads | | | | | |
|-------------------------|--------|--------|--------|---------|---------|
| | 1QFY18 | 4QFY18 | 1QFY19 | (% YoY) | (% QoQ) |
| Yield on AUMs (%) | 11.5% | 10.9% | 11.2% | -34bps | 29bps |
| Cost of funds (%) | 8.3% | 7.8% | 7.9% | -33bps | 17bps |
| Spreads (%) | 3.2% | 3.1% | 3.2% | -1bps | 12bps |
| Incremental Spreads (%) | 3.0% | 2.8% | 2.8% | -16bps | 4bps |



IHFL classifies only NPLs (90d DPD) under stage 3

Figure 3

| AUM | Jun-17 | | Jun-18 | |
|------------------------|--------|-------|--------|---------|
| | Rsbn | % AUM | Rsbn | % loans |
| Stage 1 & 2 (standard) | 937 | 99% | 1,250 | 99% |
| Stage 3 (NPL) | 7.6 | 0.8% | 9.8 | 0.8% |
| Total | 944 | | 1,260 | |

Figure 4

| Provisions held against loans | | |
|---|-------|--------------------------------|
| | Jun-1 | 18 |
| | Rsbn | % of gross NPL (stage 3 loans) |
| Total AUM | 1,260 | |
| Stage 3 AUM (NPL) | 9.8 | |
| Provisions | | |
| - Direct provisions against stage 3 loans | 2.5 | 25% |
| - Other provisions required under ECL norms | 3.2 | |
| - Floating provisions | 10.5 | |
| Total provisions | 16.2 | |

Source: Company, CLSA

Figure 5

| D-L | 4.OEV/4.0 |
|--|-----------|
| Rsbn | 1QFY18 |
| | |
| Net profit after tax as per Indian GAAP | 7.88 |
| Net profit after tax as per Ind AS | 8.09 |
| % of Indian GAAP profit | 103% |
| | |
| Adjustments | |
| On account of effective interest rate method for financial assets and liabilities recognised at amortised cost | (0.72) |
| On account of net gain on excess interest spread on assignment transactions for the quarter | 0.64 |
| On account of Expected Credit Loss | 0.09 |
| On account of fair valuation of employee stock options | (0.04) |
| Tax Impact on above including reversal of Deferred Tax Liability on 36 | 0.19 |

Reconciliation of 1QFY18 profit as per Ind AS and Indian GAAP

Source: Company, CLSA

(1) (viii) for the quarter

Figure 6

Total

| Net worth as per Ind AS can |
|-----------------------------|
| be 18% higher than in |
| Indian GAAP |

Profits under Ind AS are higher than in Indian GAAP

...as lower tax rates and credit costs offset lower NII and ESOP costs

...due to MTM gains on stake held in Oak North and reversal of DTL

| Figure 6 | |
|---|--------|
| Reconciliation of March 2018 net worth under Ind AS | |
| Rsbn | Mar 18 |
| Net worth under IGAAP | 134 |
| MTM gains on stake held in Oak North | 19 |
| Reversal of DTL | 5 |
| Net worth under Ind AS (Indicative) | 158 |
| % of net worth under Indian GAAP | 118% |

Source: CLSA

0.21




Figure 7



Source: Company, CLSA


Figure 9


Home loans form ~60% of AUMs



Source: Company, CLSA


Figure 11





Source: Company, CLSA


Figure 8



Source: Company, CLSA

Figure 10

Share of home loans has been rising and company targets to increase it to 66% by FY20



Source: Company, CLSA

Figure 12

Spreads have improved post rate hike in April 2018







Figure 13


Incremental spreads are lower than the spread on stock but the gap has been in a narrow range



Source: Company, CLSA

Figure 15


Bonds dominate, but share of ECB in incremental funding has increased



Note: Does not include sell-downs. Source: Company, CLSA

Figure 14


The gap between incremental cost of borrowings has narrowed



Source: Company, CLSA

Figure 1

Securitised book grew by 48% YoY to 11% of AUM



Source: Company, CLSA

Figure 17

Gross NPL ratio was stable at 0.8% of AUM

(Rsm)

12,000

10,000

8,000


4,000

10FY18 2QFY18 3QFY18 4QFY18 1QFY19 0.0%

Represents stage 3 loans under Ind AS. Source: Company, CLSA

Figure 18

Figure 19





We expect 26% Cagr in NII over FY18-21...

Profits to expand at 23% Cagr; FY18 profits also include some income from stake sale in OakNorth

Figure 20

| Summary income statement | | | | | |
|-----------------------------|---------|----------|---------|---------|---------|
| Year to March (Rsm) | FY17 | FY18A/CL | FY19CL | FY20CL | FY21CL |
| Interest income | 107,082 | 130,619 | 173,645 | 227,424 | 288,678 |
| Interest expense | 64,108 | 76,539 | 107,895 | 142,539 | 181,773 |
| Net interest income | 42,975 | 54,081 | 65,750 | 84,885 | 106,905 |
| Other income | 9,935 | 15,785 | 11,741 | 13,443 | 15,507 |
| - Fee income | 2,918 | 2,918 | 3,210 | 3,852 | 4,622 |
| - Profit on investments | 4,701 | 9,420 | 4,395 | 4,835 | 5,415 |
| Total income | 52,910 | 69,865 | 77,491 | 98,328 | 122,412 |
| Operating expenses | 7,363 | 8,896 | 11,475 | 13,951 | 16,697 |
| Pre-provision profit | 45,547 | 60,969 | 66,016 | 84,376 | 105,716 |
| Provisions | 7,829 | 11,213 | 4,801 | 6,195 | 7,934 |
| PBT | 37,718 | 49,756 | 61,215 | 78,181 | 97,782 |
| Tax | 8,633 | 11,501 | 15,757 | 20,456 | 25,670 |
| Net Profit | 29,086 | 38,255 | 45,458 | 57,725 | 72,112 |
| Less: minority / associates | 22 | (219) | (241) | (265) | (291) |
| Net profit post minority | 29,064 | 38,474 | 45,699 | 57,990 | 72,403 |

Source: Company, CLSA

Figure 21

| Summary balance sheet | | | | | |
|-----------------------------|-----------|-----------|-----------|-----------|-----------|
| As at March (Rsm) | FY17 | FY18A/CL | FY19CL | FY20CL | FY21CL |
| Loans | 830,877 | 1,101,800 | 1,428,776 | 1,832,634 | 2,330,511 |
| Investments | 136,166 | 148,709 | 155,856 | 163,360 | 171,240 |
| Current assets/others | 11,496 | 19,352 | 21,171 | 23,288 | 25,617 |
| Cash | 56,825 | 47,478 | 92,601 | 119,707 | 146,668 |
| Net fixed assets | 1,011 | 1,110 | 1,166 | 1,224 | 1,285 |
| Goodwill | 678 | 578 | 578 | 578 | 578 |
| Total assets | 1,037,054 | 1,319,028 | 1,700,148 | 2,140,792 | 2,675,898 |
| Share Capital | 848 | 853 | 853 | 853 | 853 |
| Reserves & Surplus | 120,373 | 133,382 | 181,341 | 214,466 | 257,057 |
| Shareholders' Funds | 121,221 | 134,235 | 182,194 | 215,319 | 257,911 |
| Borrowings | 719,206 | 922,940 | 1,209,412 | 1,568,469 | 2,001,515 |
| Other Loans | 133,805 | 179,660 | 220,075 | 259,690 | 309,428 |
| Current liabilities & prov. | 62,822 | 82,193 | 88,467 | 97,314 | 107,045 |
| Total liabilities | 1,037,054 | 1,319,028 | 1,700,148 | 2,140,792 | 2,675,898 |
| Total AUM | 913,010 | 1,226,000 | 1,600,208 | 2,065,131 | 2,644,681 |
| | | | | | • |

Expect AUM growth of 29% Cagr over FY18-21



Figure 22

| Figure 22 | | | | | |
|--------------------------------|-------|----------|--------|--------|--------|
| Key ratios | | | | | |
| Year to March | FY17 | FY18A/CL | FY19CL | FY20CL | FY21CL |
| EPS (Rs) | 69 | 90 | 107 | 136 | 170 |
| EPS growth (% YoY) | 14% | 32% | 18% | 27% | 25% |
| BVPS (Rs) | 286 | 315 | 427 | 505 | 605 |
| Adj. BVPS (Rs) | 287 | 325 | 432 | 503 | 595 |
| ROA (%) | 3.2% | 3.3% | 3.0% | 3.0% | 3.0% |
| Core ROA (%) | 2.9% | 3.0% | 3.0% | 3.0% | 3.0% |
| ROE (%) | 25% | 30% | 29% | 29% | 31% |
| Core ROE (%) | 23% | 28% | 29% | 29% | 31% |
| Spreads (%) | 4.4% | 4.2% | 3.9% | 3.8% | 3.8% |
| NIM (%) | 5.4% | 5.0% | 4.7% | 4.7% | 4.7% |
| Gross NPLs (% of loans) | 0.9% | 0.9% | 0.9% | 0.9% | 0.9% |
| Net NPLs (% of loans) | 0.4% | 0.4% | 0.6% | 0.6% | 0.6% |
| Coverage (% of gross NPLs) | 58% | 56% | 30% | 30% | 30% |
| Capital Adequacy Ratio (% RWA) | 18.3% | 18.4% | 16.9% | 15.7% | 15.0% |
| - Tier I CAR (% RWA) | 15.1% | 13.3% | 14.5% | 13.6% | 13.2% |
| Cost/ Income ratio (%) | 14% | 13% | 15% | 14% | 14% |
| Fee income growth (% YoY) | (8%) | 0% | 10% | 20% | 20% |
| Fee (% total revenue) | 5.5% | 4.2% | 4.1% | 3.9% | 3.8% |
| Cost Asset Ratio (%) | 0.8% | 0.8% | 0.8% | 0.7% | 0.7% |
| Loan Growth (% YoY) | 36% | 33% | 30% | 28% | 27% |
| Equity / Assets (%) | 12% | 10% | 11% | 10% | 10% |
| Equity / Loans (%) | 15% | 12% | 13% | 12% | 11% |
| Provision/ avg. loans (%) | 1.1% | 1.2% | 0.4% | 0.4% | 0.4% |
| Tax rates (% of PBT) | 23% | 23% | 26% | 26% | 26% |
| Yield on Loans (%) | 13.2% | 12.0% | 12.4% | 12.6% | 12.6% |
| Cost of funds (%) | 8.7% | 7.8% | 8.6% | 8.8% | 8.8% |
| Dividend per share (Rs) | 27 | 41 | 40 | 48 | 58 |
| Dividend payout (% of profit) | 39% | 45% | 37% | 35% | 34% |
| Dividend yield (%) | 2.1% | 3.2% | 3.1% | 3.7% | 4.4% |
| P/E (x) | 19 | 14 | 12 | 10 | 8 |
| P/PPP (x) | 12 | 9 | 8 | 7 | 5 |
| P/B (x) | 4.5 | 4.1 | 3.0 | 2.6 | 2.1 |
| Adjusted P/B (x) | 4.5 | 4.0 | 3.0 | 2.6 | 2.2 |
| | | | | | |



Valuation details

We value Indiabulls Housing Finance based on an adjusted PB multiple, which we prefer over reported BVPS as it normalises provisioning by building in 100% coverage on NPLs. Our target price is based on 3.2x Jun-20CL adjusted PB, which in turn is based on the Gordon Growth Model.

Investment risks

The key risk to our view is a sharp rise in interest rates that can put pressure on earnings especially as Indiabulls Housing Finance depends on wholesale sources of funding. We also believe that the company will continue to see an improvement in its funding profile (with credit rating upgrades) over one or two years; any delay on that front would be disappointing. On the business side, slower growth in demand for mortgages can also put our earnings estimates at risk.





Research subscriptions

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email_alert/.


Companies mentioned

Indiabulls Housing (IHFL IS - RS1,298.55 - BUY) HDFC (HDFC IB - RS1,932.7 - BUY) OakNorth (N-R)

Analyst certification

The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.


Important disclosures



| Date | Rec | Target | Date | Rec | Target |
|-------------|-----|----------|-------------|-----|----------|
| LATEST | BUY | 1,700.00 | 21 Jan 2017 | BUY | 950.00 |
| 22 Apr 2018 | BUY | 1,650.00 | 30 Nov 2016 | BUY | 930.00 |
| 24 Jan 2018 | BUY | 1,620.00 | 18 Oct 2016 | BUY | 1,010.00 |
| 07 Sep 2017 | BUY | 1,500.00 | 26 Jul 2016 | BUY | 870.00 |
| 25 Jul 2017 | BUY | 1,380.00 | 26 Apr 2016 | BUY | 800.00 |
| 02 May 2017 | BUY | 1,200.00 | 13 Nov 2015 | BUY | 850.00 |
| 25 Apr 2017 | BUY | 1,170.00 | 22 Oct 2015 | BUY | 860.00 |

Source: CLSA





Date Rec **Target** Date Rec **Target** 31 Jul 2018 **BUY** 2,480.00 31 Jan 2017 **BUY** 1,630.00 19 Jul 2018 **BUY** 2,430.00 30 Nov 2016 **BUY** 1,570.00 15 Jan 2018 **BUY** 2.200.00 28 Jul 2016 **BUY** 1,650.00 28 Apr 2017 **BUY** 1.900.00 28 Jan 2016 **BUY** 1.440.00 01 Apr 2017 **BUY** 02 Sep 2015 BUY 1,510.00 1.800.00

Source: CLSA

The policy of CLSA and CL Securities Taiwan Co., Ltd. ("CLST") is to only publish research that is impartial, independent, clear, fair, and not misleading. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read in conjunction with the research disclaimer as set out at www.clsa.com/disclaimer.html and the applicable regulation of the concerned market where the analyst is stationed and hence subject to. Investors are strongly encouraged to review this disclaimer before investing.

Neither analysts nor their household members/associates/may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

Unless specified otherwise, CLSA/CLST or its respective affiliates, did not receive investment banking/non-investment banking income from, and did not manage/co-manage a public offering for, the listed company during the past 12 months, and it does not expect to receive investment banking compensation from the listed company within the coming three months. Unless mentioned otherwise, CLSA/CLST does not own 1% or more of any class of securities of the subject company, and does not make a market, in the securities.

The analysts included herein hereby confirm that they have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts attest that they were not in possession of any material, non-public information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the

company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, nonpublic information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

CLSA or CLST (and/or their respective affiliates) participated in a public offering of Housing Development Finance Corp Ltd's securities or received compensation for investment banking services from Housing Development Finance Corp Ltd in the past 12 months.

CLSA, CLSA Americas and/or CLST (and/or their respective affiliates) managed or co-managed a public offering of Housing Development Finance Corp Ltd's securities in the past 12 months.

CLSA, CLSA Americas and/or CLST (and/or their respective affiliates) own(s) 0.5% (net long) or more of Indiabulls Housing Finance Ltd.

Key to CLSA/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF: Total expected return below 20% but exceeding market return; U-PF: Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

We define as "Double Baggers" stocks we expect to yield 100% or more (including dividends) within three years at the time the stocks are introduced to our "Double Bagger" list. "High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns. The list for each market is monitored weekly.

Overall rating distribution for CLSA/CLST only Universe: Overall rating distribution: BUY / Outperform - CLSA: 69.20%; CLST only: 67.44%, Underperform / SELL - CLSA: 30.53%; CLST only: 32.55%, Restricted - CLSA: 0.00%; CLST only: 0.00%. Data as of 30 June 2018. Investment banking clients as a % of rating category: BUY / Outperform - CLSA: 2.05%; CLST only: 0.00%, Underperform / SELL - CLSA: 1.16%; CLST only: 0.00%, Restricted - CLSA: 0.00%; CLST only: 0.00%. Data for 12-month period ending 30 June 2018.

There are no numbers for Hold/Neutral as CLSA/CLST do not



have such investment rankings. For a history of the recommendation, price targets and disclosure information for companies mentioned in this report please write to: CLSA Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; (c) CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone (886) 2 2326 8188). EVA® is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA estimates, "CT" stands for CLST estimates, "CRR" stands for CRR Research estimates and "CS" for Citic Securities estimates unless otherwise noted in the source.

This publication/communication is subject to and incorporates the terms and conditions of use set out on the www.clsa.com website (https://www.clsa.com/disclaimer.html). Neither publication/communication nor any portion hereof may be reprinted, sold, resold, copied, reproduced, distributed, redistributed, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of CLSA and/or CLST. CLSA and/or CLST has/have produced this publication/communication for private circulation to professional, institutional and/or wholesale clients only, and may not be distributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA, and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of CLSA and/or CLST at the date of this publication/communication and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA and/or CLST. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

This publication/communication is for information purposes only and it does not constitute or contain, and should not be considered as an offer or invitation to sell, or any solicitation or invitation of any offer to subscribe for or purchase any securities in any jurisdiction and neither this publication/communication nor anything contained herein shall form the basis of any investment decision, contract or commitment whatsoever. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual Before acting on any information publication/communication, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including tax advice. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. The value of any investment or income my go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. CLSA and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this publication/communication or its contents.

To maintain the independence and integrity of our research, our Corporate Finance, Sales Trading, Asset Management and Research business lines are distinct from one another. This means that CLSA's Research department is not part of and does not report to CLSA Corporate Finance department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance nor the Sales and

Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management. CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading, Asset Management and Research activities. Some examples of these controls include: the use of information barriers and other controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance, Asset Management, and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's research.

Subject to any applicable laws and regulations at any given time, CLSA, CLST, their respective affiliates, officers, directors or employees may have used the information contained herein before publication and may have positions in, or may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided corporate finance/capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, you should be aware that CLSA and/or CLST and/or their respective affiliates, officers, directors or employees may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation and the full details are available at http://www.clsa.com/member/research_disclosures/. Disclosures therein include the position of CLSA and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits the subject company, covered in publication/communication, or from any third party. If investors have any difficulty accessing this website, please contact webadmin@clsa.com on +852 2600 8111. If you require disclosure previous please information on dates. compliance_hk@clsa.com.

This publication/communication is distributed for and on behalf of CLSA Limited (for research compiled by non-US and non-Taiwan analyst(s)), and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd; in Hong Kong by CLSA Limited; in India by CLSA India Private Limited, (Address: 8/F. Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271; U67120MH1994PLC083118; SEBI Registration No: INZ000001735 as Stock Broker, INM000010619 as Merchant Banker and INH000001113 as Research Analyst,; in Indonesia by PT CLSA Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd; in Korea by CLSA Securities Korea Ltd; in Malaysia by CLSA Securities Malaysia Sdn Bhd; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Singapore by CLSA Singapore Pte Ltd and solely to persons who qualify as an institutional investor, accredited investor or expert investor; in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST and in United Kingdom by CLSA (UK).

United States of America: Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas. However, the delivery of this research report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

United Kingdom: In the United Kingdom, this research is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence



of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The research is disseminated in the EU by CLSA (UK), which is authorised and regulated by the Financial Conduct Authority. This document is directed at persons having professional experience in matters relating to investments as defined in Article 19 of the FSMA 2000 (Financial Promotion) Order 2005. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating to investments you should not rely on this document. Where the research material is

compiled by the UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules this research is prepared and intended as substantive research material.

For all other jurisdiction-specific disclaimers please refer to https://www.clsa.com/disclaimer.html. The analysts/contributors to this publication/communication may be employed by any relevant CLSA entity or CLST, which is different from the entity that distributes the publication/communication in the respective jurisdictions.© 2018 CLSA Limited and/or CL Securities Taiwan Co., Ltd. ("CLST").